Engineering luminescent biosensors for point-of-care SARS-CoV-2 antibody detection
| العنوان: | Engineering luminescent biosensors for point-of-care SARS-CoV-2 antibody detection |
|---|---|
| المؤلفون: | Leonel Torres, James Byrnes, Anum A. Glasgow, Michael J. Peluso, Taia T. Wang, Timothy J. Henrich, Kevin Leung, Alexander J. Martinko, Nikita S. Iyer, Xin X. Zhou, James A. Wells, Katarina Pance, Keirstinne Turcios, Cristina M. Tato, Bryan Greenhouse, Jeff E. Glasgow, Susanna K. Elledge, Shion A. Lim, Irene Lui |
| المصدر: | Nat Biotechnol medRxiv article-version (status) pre article-version (number) 1 Nature biotechnology, vol 39, iss 8 |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Saliva, Luminescence, Biosensing Techniques, Antibodies, Viral, Applied Microbiology and Biotechnology, Serology, 0302 clinical medicine, Medicine, Viral, Lung, Whole blood, 0303 health sciences, education.field_of_study, screening and diagnosis, biology, Chemistry, Vaccination, Detection, Infectious Diseases, Molecular Medicine, Antibody, Infection, Biotechnology, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Point-of-Care Systems, Population, Biomedical Engineering, Bioengineering, Antibodies, Article, COVID-19 Serological Testing, Vaccine Related, 03 medical and health sciences, Biodefense, Humans, Luciferase, education, 030304 developmental biology, Point of care, business.industry, SARS-CoV-2, Prevention, COVID-19, Virology, 4.1 Discovery and preclinical testing of markers and technologies, Emerging Infectious Diseases, Good Health and Well Being, biology.protein, Immunization, business, Biosensor, 030217 neurology & neurosurgery |
| الوصف: | Current serology tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies mainly take the form of enzyme-linked immunosorbent assays, chemiluminescent microparticle immunoassays or lateral flow assays, which are either laborious, expensive or lacking sufficient sensitivity and scalability. Here we present the development and validation of a rapid, low-cost, solution-based assay to detect antibodies in serum, plasma, whole blood and to a lesser extent saliva, using rationally designed split luciferase antibody biosensors. This new assay, which generates quantitative results in 30 min, substantially reduces the complexity and improves the scalability of coronavirus disease 2019 (COVID-19) antibody tests. This assay is well-suited for point-of-care, broad population testing, and applications in low-resource settings, for monitoring host humoral responses to vaccination or viral infection. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f1c6c05844561f1bb9ccc000d7b7cef https://europepmc.org/articles/PMC8355051/ |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....8f1c6c05844561f1bb9ccc000d7b7cef |
| قاعدة البيانات: | OpenAIRE |
| الوصف غير متاح. |